Precision Point Staffing ™

We are beyond excited to officially welcome Eddie Emery to the Precision Point Staffing ™ team! When we started this company, we talked a lot about what kind of people we wanted to build around including genuine, driven, empathetic individuals who not only excel at what they do but elevate the people around them. Eddie embodies all of that and more. He’s kind, sharp, thoughtful, and an incredible recruiter who approaches this industry with the same heart and intentionality that we’ve built Precision Point on. From our first conversation, it was clear he understood what we’re about. Eddie joining us marks an important step for our growing team, and we couldn’t be more proud of where we’re headed next. Please help us in giving Eddie Emery warm welcome!

M&A, Money, and Mayhem... These are some events that shaped BioPharma in May. 🔄 Acquisitions Sanofi announced its acquisition of Vigil Neuroscience for up to $470 million, aiming to bolster its neurological drug portfolio, particularly in Alzheimer's treatment. ACELYRIN, INC. is set to merge with Alumis, Inc. in an all-stock deal, creating a combined entity with a robust late-stage portfolio and a cash runway of approximately $737 million. 💰 Funding Highlights Moderna secured $176 million to expedite the creation of a pandemic influenza vaccine targeting potential bird flu infections. SciLeads Etiome raised $50 million in Series A funding to advance its Temporal Biodynamics platform for developing preemptive medicines targeting chronic and progressive diseases. 📉 Layoffs and Restructuring Eikon Therapeutics is laying off 55 employees, attributing the decision to reduced federal research funding and a broader downturn in biotech investments. UNITY Biotechnology announced the layoff of its entire remaining workforce as part of a cost-cutting initiative, exploring strategic alternatives such as asset sales or a full shutdown. Biomea Fusion is reducing its workforce by 35% to conserve cash and shift focus toward diabetes and obesity programs. Mammoth Biosciences laid off 24 employees as part of a strategic realignment to advance internal programs and support partnerships. Tempest Therapeutics cut approximately 80% of its workforce to extend its cash runway while exploring strategic alternatives, including mergers or acquisitions. These developments reflect the dynamic nature of the biopharma industry, with significant investments and strategic shifts occurring amidst funding challenges and organizational restructuring.

-Some April news for the biotech sector- Acquisitions 💰 Merck to acquire SpringWorks Therapeutics for $3.9B in an all cash deal 💸 This move will absolutely bolster its rare cancer therapies portfolio. Novartis to acquire Regulus Therapeutics for $1.7B 💸 allowing access to their Phase 3 ready kidney drug farabursen. Approvals ✔️ Abeona Therapeutics announced FDA approval for Zevaskyn, treating epidermolysis bullosa which is a rare connective tissue disorder. Akeso Biopharma announced FDA approval for penpulimab-kcqxnasopharyngeal, treating a agressive type of cell carcinoma. More Novartis... announced FDA approval for Vanrafia, which is used for proteinuria reduction in primary immunoglobulin (IgA) nephropathy. Sanofi announced FDA approval for Qfitlia for the treatment of Hemophilia A or B.

We got big news from Eli Lilly.. Eli Lilly has just announced results from its Phase 3 trial of orforglipron, an oral GLP-1 receptor agonist designed for weight loss and type 2 diabetes. In this trial, patients saw 8% weight reduction and improved blood sugar levels all in a daily pill form (no injections) with no food or water restrictions. This could redefine convenience and compliance in the growing GLP-1 market currently dominated by injectables. 💊🔥 In parallel, Lilly is investing $3B into expanding U.S. manufacturing, aiming to scale up production and create over 750 new jobs in Wisconsin — a major win for both healthcare and our U.S. biotech infrastructure. The future of metabolic health is accelerating. Let’s go. 🚀 #biotechnews #GLP1 #WeightLoss #DiabetesCare #EliLilly #Innovation #LifeSciences #HealthTech

Another big move within the Gene Therapy space! This time Atsena Therapeutics secures the bag with 150 Million in Series C! 💰 This follows other great news that Atsena announced back in March - the company received Fast Track Designation from the FDA for ATSN-201, its gene therapy aimed at treating X-linked retinoschisis. Congrats Patrick Ritschel and wider team!

Big Moves in the Gene Therapy space coming at you live from the SF Bay Area. 🌉 👀 4D Molecular Therapeutics and Adverum Biotechnologies advance their gene therapy treatments for wet AMD into Phase 3 trials! 👀 🔬 4DMT’s 4D-150 (4FRONT-1 Trial) is targeting sustained anti-VEGF delivery with fewer injections. First patients are already enrolled! ⚡ Adverum’s Ixo-vec AKA ARTEMIS Trial is pushing a one-time intravitreal gene therapy that could transform treatments as we know it. Why does this matter? A single gene therapy dose could change the game of treatment by replacing years of frequent injections. 💬 What are your thoughts on gene therapy reshaping the ophthalmology? Are we close to eliminating the need for routine injections? We would love to hear your thoughts! ⬇️

Very unfortunate news for CARGO Therapeutics. Always sad to see another cell therapy company wind down, especially given the immense potential these treatments have. https://lnkd.in/egaUyCbp

Happy to share some exciting news in the cell therapy space... Orca Bio reports positive results from its pivotal Phase 3 Precision-T study, evaluating the investigational allogeneic T-cell immunotherapy in patients with hematologic malignancies. This study met its primary endpoint, which demonstrated a statistically significant improvement in survival free of moderate-to-severe chronic graft-versus-host disease compared to conventional allogeneic hematopoietic stem cell transplant. We look forward to seeing the Orca team join the approved therapies space with big names like Novartis' - Kymirah, Kite Pharma's - Yescarta , and Bristol Myers Squibb's - Breyanzi. Congrats to Ivan Dimov, Jeroen Bekaert, Nathaniel Fernhoff and the rest of the Orca team.

AI in Drug Discovery... Is AI the Hottest Trend of 2025? Or will we continue with the autoimmune boom? 💥 AI-driven drug discovery is transforming biotech, with players like Retro Biosciences, Calico Life Sciences, and Altos Labs leading the way. 🧠💊 But what is interesting? We are seeing more small players getting into the field such as Arda Therapeutics led by Adam Freund and NewLimit led by Jacob Kimmel, Brian Armstrong, and Blake Byers Fun Fact: Did you know AI-developed drugs are now reaching clinical trials in half the time compared to traditional methods? 💥

We're #hiring a new Amazon Advertising Manager in Los Angeles, California. Apply today or share this post with your network.